- Clinical evidence and tumor testing data are essential in determining pathogenicity of truncating alterations is the 3’ end of genes.
- Identifying the most distal known pathogenic mutation would provide evidence to classify other C-terminal truncating alterations.
- As evidence used in classifying these alterations may be dependent on unique data from the laboratory, the need for continued data sharing among commercial laboratories is critical.